Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefepime Hydrochloride

FDA-approved product (injectable, injection), marketed as Cefepime And Dextrose In Duplex Container, Cefepime Hydrochloride, Cefepime Hydrochloride In Plastic Container and 2 more.

Registered studies
50+
Lab records
203
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cefepime Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacteriemia
  • Infection
  • Pneumonia
  • Pyelonephritis
  • Sprain
  • Urinary tract infection
  • Ventilator-associated pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fourth-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DE01

Repurposing investigation

Cefepime Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli98.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis50.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 95 of 203 lab records
Open Cefepime Hydrochloride in ChEMBL Registered studies below
Show the latest 150 of 203 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefepime Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA

    NCT07283068 · start 2026-06-15

    Registered record
    Registry ID
    NCT07283068
    Conditions
    Revision Total Knee Arthroplasty
    Interventions
    Intraosseous Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-06-15
    Completion
    2030-06-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRevision Total Knee Arthroplasty
    InterventionIntraosseous Vancomycin
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients

    NCT07484633 · start 2026-04

    Registered record
    Registry ID
    NCT07484633
    Conditions
    Infection; Sepsis; NICU; PICU; Beta Lactams
    Interventions
    Extended infusion time of the following beta-lactam: meropenem; Short-term infusion time of the following beta-lactam: meropenem; Extended infusion time of the following beta-lactam: piperacillin/tazobactam; Extended infusion time of the following beta-lactam: cefepime; Extended infusion time of the following beta-lactam: ceftriaxone; Short-term infusion time of the following beta-lactam: piperacillin/tazobactam; Short-term infusion time of the following beta-lactam: cefepime; Short-term infusion time of the following beta-lactam: ceftriaxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-04
    Completion
    2028-04
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Sepsis; NICU; PICU +1 more
    InterventionExtended infusion time of the following beta-lactam: meropenem; Short-term infusion time of the following beta-lactam: meropenem; Extended infusion time of the following beta-lactam: piperacillin/tazobactam; Extended infusion time of the following beta-lactam: cefepime +4 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • Cefotetan Therapy for Escherichia Coli Infections

    NCT07318584 · start 2026-03

    Registered record
    Registry ID
    NCT07318584
    Conditions
    E Coli Infection; ESBL Producing E.Coli
    Interventions
    Cefotetan; Carbapenems; Beta Lactam Antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2028-08
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionE Coli Infection; ESBL Producing E.Coli
    InterventionCefotetan; Carbapenems; Beta Lactam Antibiotics
    PhasePhase 2
    Registry statusNot yet recruiting

  • BLOOM: Pragmatic Feasibility Trial

    NCT07287332 · start 2026-01-15

    Registered record
    Registry ID
    NCT07287332
    Conditions
    Sepsis; Infection
    Interventions
    Up-front individualized dosing algorithm; Usual Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-01-15
    Completion
    2027-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; Infection
    InterventionUp-front individualized dosing algorithm; Usual Care
    PhaseNot applicable
    Registry statusRecruiting

  • Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP

    NCT06168734 · start 2025-06

    Registered record
    Registry ID
    NCT06168734
    Conditions
    Ventilator-associated Pneumonia; Hospital-acquired Pneumonia
    Interventions
    Cefepime-taniborbactam; Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2025-06
    Completion
    2027-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator-associated Pneumonia; Hospital-acquired Pneumonia
    InterventionCefepime-taniborbactam; Meropenem
    PhasePhase 3
    Registry statusWithdrawn

  • Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

    NCT06406114 · start 2025-05-05

    Registered record
    Registry ID
    NCT06406114
    Conditions
    Drug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy; Beta Lactam Adverse Reaction; Drug-Induced Anaphylaxis; Cephalosporin Reaction
    Interventions
    Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge; Amoxicillin double-blind placebo-controlled drug challenge
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-05
    Completion
    2028-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy +3 more
    InterventionBeta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

    NCT06709521 · start 2025-02-12

    Registered record
    Registry ID
    NCT06709521
    Conditions
    Bacterial Infection
    Interventions
    Iohexol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2025-02-12
    Completion
    2026-07-02
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infection
    InterventionIohexol
    PhasePhase 4
    Registry statusCompleted

  • A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.

    NCT06806995 · start 2025-01-21

    Registered record
    Registry ID
    NCT06806995
    Conditions
    PHA1A
    Interventions
    Zidebactam-Cefepime; Metronidazole; FEP-ZID
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-01-21
    Completion
    2025-02-17
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPHA1A
    InterventionZidebactam-Cefepime; Metronidazole; FEP-ZID
    PhasePhase 1
    Registry statusCompleted

  • Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty

    NCT06384651 · start 2024-12-03

    Registered record
    Registry ID
    NCT06384651
    Conditions
    Infections; Ankle Arthritis
    Interventions
    Intraosseous Vancomycin Injection; Intravenous Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-12-03
    Completion
    2027-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections; Ankle Arthritis
    InterventionIntraosseous Vancomycin Injection; Intravenous Vancomycin
    PhasePhase 4
    Registry statusRecruiting

  • Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients

    NCT06338345 · start 2024-09-01

    Registered record
    Registry ID
    NCT06338345
    Conditions
    Cardiogenic Shock; Post-cardiac Surgery; Cardiac Arrest; Extracorporeal Membrane Oxygenation Complication; Infections
    Interventions
    Therapeutic drug monitoring of beta-lactam
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2024-09-01
    Completion
    2028-09-01
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiogenic Shock; Post-cardiac Surgery; Cardiac Arrest; Extracorporeal Membrane Oxygenation Complication +1 more
    InterventionTherapeutic drug monitoring of beta-lactam
    PhaseNot applicable
    Registry statusNot yet recruiting

  • PMT for MDRO Decolonization

    NCT05632315 · start 2024-08-19

    Registered record
    Registry ID
    NCT05632315
    Conditions
    Multidrug Resistant Bacterial Infection; Enterobacteriaceae Infections; Pseudomonas Aeruginosa; VRE Infection; Methicillin-resistant Staphylococcus Aureus
    Interventions
    PMT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-08-19
    Completion
    2026-08
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug Resistant Bacterial Infection; Enterobacteriaceae Infections; Pseudomonas Aeruginosa; VRE Infection +1 more
    InterventionPMT
    PhasePhase 2
    Registry statusActive not recruiting

  • Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

    NCT06080698 · start 2024-02-22

    Registered record
    Registry ID
    NCT06080698
    Conditions
    Gram-negative Bacteremia
    Interventions
    Intravenous Antibiotics; Oral Antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-02-22
    Completion
    2027-06-30
    Enrolment
    1,030

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-negative Bacteremia
    InterventionIntravenous Antibiotics; Oral Antibiotics
    PhaseNot applicable
    Registry statusRecruiting

  • IO vs IV Vancomycin in Tourniquetless TKA

    NCT05705843 · start 2023-01-25

    Registered record
    Registry ID
    NCT05705843
    Conditions
    Infection, Surgical Site
    Interventions
    Intraosseous Vancomycin Injection; Intravenous Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-01-25
    Completion
    2024-01-25
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Surgical Site
    InterventionIntraosseous Vancomycin Injection; Intravenous Vancomycin
    PhasePhase 4
    Registry statusUnknown

  • Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

    NCT04979806 · start 2022-08-28

    Registered record
    Registry ID
    NCT04979806
    Conditions
    Complicated Urinary Tract Infection; Acute Pyelonephritis
    Interventions
    Cefepime-zidebactam (FEP-ZID); Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-08-28
    Completion
    2024-11-25
    Enrolment
    530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection; Acute Pyelonephritis
    InterventionCefepime-zidebactam (FEP-ZID); Meropenem
    PhasePhase 3
    Registry statusCompleted

  • Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia

    NCT04948463 · start 2021-11-15

    Registered record
    Registry ID
    NCT04948463
    Conditions
    Febrile Neutropenia
    Interventions
    Piperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection; Amikacin Injection; Ciprofloxacin; Piperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection; Amikacin Injection; Ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-11-15
    Completion
    2025-12-17
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    InterventionPiperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection +8 more
    PhasePhase 4
    Registry statusCompleted